IMNN-001 Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for IMNN-001 comprises 3 peer-reviewed publications across 3 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Fallopian Tube Neoplasms. Most recent publication: OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer., Gynecol Oncol, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial.
    Yin X, Davi R, Lamont EB, et al. · JCO Clin Cancer Inform · 2023
    PubMed: PMID 36608308 · NCT02480374 · Fallopian Tube Neoplasms
  2. OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
    Thaker PH, Richardson DL, Hagemann AR, et al. · Gynecol Oncol · 2025
    PubMed: PMID 40461366 · NCT03393884 (OVATION 2) · Fallopian Tube Neoplasms
  3. SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors.
    Gonzalez-Junca A, Liu FD, Nagaraja AS, et al. · Mol Cancer Ther · 2022
    PubMed: PMID 34210826 · NCT02480374 · Fallopian Tube Neoplasms

Publications by year

2022–2025: 3 publications.

2022
1
2023
1
2025
1

Publications by indication

Fallopian Tube Neoplasms (3)

  • OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
    Gynecol Oncol · 2025 · PMID 40461366 · NCT03393884
  • Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial.
    JCO Clin Cancer Inform · 2023 · PMID 36608308 · NCT02480374
  • SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors.
    Mol Cancer Ther · 2022 · PMID 34210826 · NCT02480374

Publications by journal

All IMNN-001 publications (3)

2025 (1 paper)

  1. OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
    Thaker PH, Richardson DL, Hagemann AR, et al. · Gynecol Oncol · 2025 · Derived
    PubMed: PMID 40461366 · NCT03393884 (OVATION 2) · Fallopian Tube Neoplasms

2023 (1 paper)

  1. Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial.
    Yin X, Davi R, Lamont EB, et al. · JCO Clin Cancer Inform · 2023 · Derived
    PubMed: PMID 36608308 · NCT02480374 · Fallopian Tube Neoplasms

2022 (1 paper)

  1. SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors.
    Gonzalez-Junca A, Liu FD, Nagaraja AS, et al. · Mol Cancer Ther · 2022 · Derived
    PubMed: PMID 34210826 · NCT02480374 · Fallopian Tube Neoplasms

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).